Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations-Reference-Cited by-同舟云学术

Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations

Published:2021-03 Issue:3 Volume:159 Page:1256-1264
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Schwalk Audra J.,Ost David E.,Saltijeral Sahara N.,De La Garza Henriette,Casal Roberto F.,Jimenez Carlos A.,Eapen Georgie A.,Lewis Jeff,Rinsurongkawong Waree,Rinsurongkawong Vadeerat,Lee Jack,Elamin Yasir,Zhang Jianjun,Roth Jack A.,Swisher Stephen,Heymach John V.,Grosu Horiana B.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference18 articles.

1. ERS/EACTS statement on the management of malignant pleural effusions;Bibby;Eur Respir J,2018

2. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters;Musani;Respiration,2004

3. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions;Putnam;Cancer,1999

4. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation;Zou;J Int Med Res,2014

5. Can EGFR-tyrosine kinase inhibitors (TKI) alone without talc pleurodesis prevent recurrence of malignant pleural effusion (MPE) in lung adenocarcinoma;Verma;Curr Drug Disc Technol,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central lung adenocarcinoma in a young male mimicking pneumonia with nonrecurrent polyserous effusions of negative cytology: A case report;Medicine;2024-08-02

2. Advances in pleural diseases;European Respiratory Journal;2024-06

3. Single‐cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non‐small‐cell lung cancer;Clinical and Translational Medicine;2024-04

4. Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion;BMC Pulmonary Medicine;2024-02-16

5. Methodologic Issues Specific to Prediction Model Development and Evaluation;CHEST;2023-11